文献速递免疫规划慢病防控与筛查卫生政策与健康促进

人乳头瘤病毒疫苗两剂次接种方案:系统综述与Meta分析

Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2017-04-25

该系统综述与Meta分析检索至2016年2月,纳入7项非劣效性试验,覆盖11个国家,比较两剂次与三剂次HPV疫苗方案。青少年女孩接种两剂次后HPV16/18抗体几何平均浓度非劣效或不明确,一项试验未发现持续HPV感染;截至2017年2月,23个中低收入国家和25个高收入国家采用两剂次方案。

要点

  • 青少年女孩两剂次HPV疫苗的HPV16/18抗体几何平均浓度非劣效或不明确,最长随访24个月。
  • 一项有临床结局的试验发现两剂次或三剂次后均无持续HPV感染发生。
  • 截至2017年2月,23个中低收入国家和25个高收入国家采用两剂次方案。

核心结论

  • 两剂次HPV疫苗方案在青少年女孩中提供令人满意的免疫学结局,但全球采用有限,尤其是在宫颈癌负担最重的国家。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Cochrane对照试验中心注册库、试验注册库和制造商数据库自最早日期至2016年2月,筛选1464条记录,纳入7项在11个国家开展的符合条件非劣效性试验。

主要发现

  • 在青少年女孩的随机比较中(3项试验),两剂次对比三剂次后HPV16和HPV18抗体几何平均浓度非劣效或不明确,随访至24个月。
  • 一项有临床结局的试验发现,两剂次或三剂次后均无持续HPV感染发生。
  • 在非随机比较中,接种两剂次的青少年女孩对比接种三剂次的女性,接种后至少21个月抗体几何平均浓度非劣效或更优。

关键数值与推荐

  • 截至2017年2月,23个中低收入国家和25个高收入国家已采用两剂次HPV疫苗接种方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Simpler schedules for human papillomavirus (HPV) vaccine delivery could improve vaccine coverage and the effectiveness of cervical cancer prevention. The objective of this study was to systematically review evidence about the effects of two-dose compared with three-dose schedules for human papillomavirus (HPV) vaccine and to describe the uptake of two-dose HPV vaccination schedules globally. We searched PubMed, the Cochrane Central Registry of Controlled Trials, trials registers, and manufacturers' databases from their earliest date to February 2016. We selected randomised controlled trials and controlled clinical trials that directly compared HPV vaccine schedules with two or three doses. We extracted data on immunological and clinical outcomes and used meta-analysis where appropriate. We also described the use of two-dose HPV vaccine schedules globally. We screened 1464 items and included seven eligible noninferiority trials in 11 countries. In randomised comparisons amongst adolescent girls (three trials), geometric mean concentrations (GMC) of antibodies against HPV16 and HPV18 were non-inferior or inconclusive, up to 24months after a two-dose compared with a three-dose schedule. One trial with a clinical outcome found no persistent HPV infections occurred after either two or three doses. In non-randomised comparisons, GMC were non-inferior or superior in adolescent girls receiving the two-dose schedule compared with women receiving the three-dose schedule for at least 21months after vaccination. By February 2017, 23 low and middle income and 25 high income countries had adopted a two-dose HPV vaccination schedule. A two-dose HPV vaccine schedule provides satisfactory immunological outcomes in adolescent girls, but uptake globally is limited, particularly in countries with the highest burden of cervical cancer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. D'Addario M, Redmond S, Scott P, et al. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. Vaccine. 2017. PMID: 28455170. doi:10.1016/j.vaccine.2017.03.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。